Arcturus Therapeutics Holdings Inc. Stock price

Equities

ARCT

US03969T1097

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
33.77 USD +2.77% Intraday chart for Arcturus Therapeutics Holdings Inc. +1.93% +7.10%
Sales 2024 * 151M Sales 2025 * 254M Capitalization 909M
Net income 2024 * -71M Net income 2025 * 2M EV / Sales 2024 * 3.62 x
Net cash position 2024 * 364M Net cash position 2025 * - EV / Sales 2025 * 3.58 x
P/E ratio 2024 *
-13.7 x
P/E ratio 2025 *
207 x
Employees 180
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.19%
More Fundamentals * Assessed data
Dynamic Chart
Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing MT
Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing MT
Transcript : Arcturus Therapeutics Holdings Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:45 AM
Canaccord Genuity Adjusts Arcturus Therapeutics Holdings' PT to $87 From $81, Maintains Buy Rating MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $58 From $45, Maintains Overweight Rating MT
Transcript : Arcturus Therapeutics Holdings Inc., Q4 2023 Earnings Call, Mar 07, 2024
Arcturus Therapeutics Swings to Q4 Net Loss, Revenue Drops MT
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q4 Revenue $34M, vs. Street Est of $37.9M MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Arcturus Therapeutics Holdings Inc. Announces Executive Changes CI
Arcturus Gets European Orphan Medicinal Product Label For ARCT-032 to Treat Cystic Fibrosis MT
Citigroup Raises Price Target on Arcturus Therapeutics to $48 From $40, Maintains Buy Rating MT
Transcript : Arcturus Therapeutics Holdings Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:00 PM
Passport Technologies, Inc. Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA Delivery Systems CI
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster CI
More news
1 day+2.77%
1 week+1.93%
Current month-12.87%
1 month-15.95%
3 months+2.43%
6 months+32.74%
Current year+7.10%
More quotes
1 week
31.76
Extreme 31.76
35.68
1 month
31.76
Extreme 31.76
40.48
Current year
29.63
Extreme 29.63
43.81
1 year
17.52
Extreme 17.52
43.81
3 years
11.70
Extreme 11.7
65.00
5 years
5.70
Extreme 5.7
129.71
10 years
4.11
Extreme 4.11
129.71
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 13-02-28
Director of Finance/CFO 59 19-08-31
Chief Tech/Sci/R&D Officer - 21-10-20
Members of the board TitleAgeSince
Director/Board Member 83 19-08-31
Director/Board Member 65 18-05-26
Chairman 81 18-05-26
More insiders
Date Price Change Volume
24-03-28 33.77 +2.77% 527,839
24-03-27 32.86 +2.27% 867,781
24-03-26 32.13 -7.65% 554,648
24-03-25 34.79 +2.63% 800,820
24-03-22 33.9 +2.32% 327,396

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
33.77 USD
Average target price
67.89 USD
Spread / Average Target
+101.03%
Consensus
  1. Stock
  2. Equities
  3. Stock Arcturus Therapeutics Holdings Inc. - Nasdaq